NASDAQ:ITRM - Iterum Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.64 +0.22 (+4.06 %) (As of 03/18/2019 04:00 PM ET)Previous Close$5.42Today's Range$5.45 - $6.0052-Week Range$4.70 - $13.00Volume21,954 shsAverage Volume9,225 shsMarket Capitalization$78.73 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland. Receive ITRM News and Ratings via Email Sign-up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ITRM Previous Symbol CUSIPN/A CIK1659323 Webwww.iterumtx.com Phone353-1903-8920Debt Debt-to-Equity Ratio0.15 Current Ratio14.05 Quick Ratio14.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales157.46 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares13,959,000Market Cap$78.73 million Next Earnings Date3/20/2019 (Estimated) OptionableNot Optionable Iterum Therapeutics (NASDAQ:ITRM) Frequently Asked Questions What is Iterum Therapeutics' stock symbol? Iterum Therapeutics trades on the NASDAQ under the ticker symbol "ITRM." How were Iterum Therapeutics' earnings last quarter? Iterum Therapeutics PLC (NASDAQ:ITRM) posted its earnings results on Wednesday, November, 14th. The company reported ($1.24) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.97) by $0.73. The business had revenue of $0.25 million for the quarter. View Iterum Therapeutics' Earnings History. When is Iterum Therapeutics' next earnings date? Iterum Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 20th 2019. View Earnings Estimates for Iterum Therapeutics. What price target have analysts set for ITRM? 5 equities research analysts have issued 12 month target prices for Iterum Therapeutics' shares. Their predictions range from $18.00 to $24.00. On average, they expect Iterum Therapeutics' stock price to reach $20.75 in the next twelve months. This suggests a possible upside of 267.9% from the stock's current price. View Analyst Price Targets for Iterum Therapeutics. What is the consensus analysts' recommendation for Iterum Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iterum Therapeutics. Has Iterum Therapeutics been receiving favorable news coverage? Press coverage about ITRM stock has been trending somewhat positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iterum Therapeutics earned a news impact score of 1.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Iterum Therapeutics' key competitors? Some companies that are related to Iterum Therapeutics include Owens & Minor (OMI), Sorrento Therapeutics (SRNE), Rockwell Medical (RMTI), Strongbridge Biopharma (SBBP), Neuronetics (STIM), Harpoon Therapeutics (HARP), Clover (CLV), AC Immune (ACIU), Syros Pharmaceuticals (SYRS), Cellular Biomedicine Group (CBMG), Merus (MRUS), Akumin (AKU), Karyopharm Therapeutics (KPTI), Medical Developments (MVP) and Benchmark (BMK). What other stocks do shareholders of Iterum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Innovate Biopharmaceuticals (INNT), Viking Therapeutics (VKTX), Snap (SNAP), Alibaba Group (BABA), QUALCOMM (QCOM), Anavex Life Sciences (AVXL), Encana (ECA), Krystal Biotech (KRYS), Puma Biotechnology (PBYI) and Intellia Therapeutics (NTLA). Who are Iterum Therapeutics' key executives? Iterum Therapeutics' management team includes the folowing people: Mr. Corey N. Fishman, Pres, CEO & Director (Age 54)Ms. Judith M. Matthews, Chief Financial Officer (Age 49)Dr. Michael W. Dunne, Chief Scientific Officer (Age 59)Mr. Benjamin M. Pe, VP of OperationsMr. John J. White, VP of Bus. Devel. & Supply Chain When did Iterum Therapeutics IPO? (ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. Who are Iterum Therapeutics' major shareholders? Iterum Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.25%). Company insiders that own Iterum Therapeutics stock include Corey N Fishman, David George Kelly, Judith M Matthews, Mark Chin, Michael W Dunne, Patrick J Heron, Paul R Edick and Sofinnova Venture Partners Ix,. View Institutional Ownership Trends for Iterum Therapeutics. Which institutional investors are selling Iterum Therapeutics stock? ITRM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Iterum Therapeutics. How do I buy shares of Iterum Therapeutics? Shares of ITRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Iterum Therapeutics' stock price today? One share of ITRM stock can currently be purchased for approximately $5.64. How big of a company is Iterum Therapeutics? Iterum Therapeutics has a market capitalization of $78.73 million and generates $500,000.00 in revenue each year. What is Iterum Therapeutics' official website? The official website for Iterum Therapeutics is http://www.iterumtx.com. How can I contact Iterum Therapeutics? Iterum Therapeutics' mailing address is BLOCK 2 FLOOR 3 HARCOURT CENTRE HARCOURT STREET, DUBLIN L2, 2. The company can be reached via phone at 353-1903-8920 or via email at [email protected] MarketBeat Community Rating for Iterum Therapeutics (NASDAQ ITRM)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 52 (Vote Outperform)Underperform Votes: 59 (Vote Underperform)Total Votes: 111MarketBeat's community ratings are surveys of what our community members think about Iterum Therapeutics and other stocks. Vote "Outperform" if you believe ITRM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ITRM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/18/2019 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?